REM Sleep In Mice Research Articles

Wakefulness Induced by TAAR1 Partial Agonism is Mediated Through Dopaminergic Neurotransmission.

Trace amine-associated receptor 1 (TAAR1) is known to negatively regulate dopamine (DA) release. The partial TAAR1 agonist RO5263397 promotes wakefulness and suppresses NREM and REM sleep in mice, rats, and non-human primates. We tested the hypothesis that the TAAR1-mediated effects on sleep/wake were due, at least in part, to DA release. Male C57BL6/J mice (n=8) were intraperitoneally administered the D1R antagonist SCH23390, the D2R antagonist eticlopride, a combination of D1R+D2R antagonists or saline at ZT5.5, followed 30 min later by RO5263397 or vehicle (10% DMSO in DI water) at ZT6 per os. EEG, EMG, subcutaneous temperature, and activity were recorded in each mouse across the 8 treatment conditions and sleep architecture was analyzed for 6 hours post-dosing. Consistent with our previous reports, RO5263397 increased wakefulness as well as the latency to NREM and REM sleep. D1, D2, and D1+D2 pretreatment reduced RO5263397-induced wakefulness during the first 1-2 hours after dosing, but only the D1+D2 combination attenuated the wake-promoting effect of RO5263397 from ZT6-8, mostly by increasing NREM sleep. Although D1+D2 antagonism blocked the wake-promoting effect of RO5263397, only the D1 antagonist significantly reduced the TAAR1-mediated increase in NREM latency. Neither the D1 nor the D2 antagonist affected TAAR1-mediated suppression of REM sleep. These results suggest that, whereas TAAR1 effects on wakefulness are mediated in part through the D2R, D1R activation plays a role in reversing the TAAR1-mediated increase in NREM sleep latency. By contrast, TAAR1-mediated suppression of REM sleep appears not to involve D1R or D2R mechanisms.

A probabilistic model for the ultradian timing of REM sleep in mice

A probabilistic model for the ultradian timing of REM sleep in mice

0354 Age-Related Spectral Changes in NREM And REM Sleep in Mice are Global and Not Local

Abstract Introduction Brain topography modulates age-related changes in the human sleep electroencephalogram, which are linked with differences in integrity of specific cortical areas and may reflect local changes in sleep homeostasis. In mice, there is conflicting evidence regarding the topography of age-related changes for NREM and REM sleep. To disambiguate this issue, we investigated in mice the topography of age-related spectral differences for REM and NREM sleep. Methods LFP electrodes were implanted in 5 cortical areas and in the hippocampus of 17 C57/BL6 mice (8 young and 9 old, mean age = 7.5 and 16 months). Mice LFPs were recorded for a week and states of vigilance were semi-automatically detected in light and dark periods (12h-12h). Spectral analysis was run on 4s windows. Values were averaged for each electrode and in each period of the light/dark cycle in REM/NREM sleep for slow delta (0.25-2Hz), delta (2-4Hz), theta (4-8Hz), sigma (10-16Hz) and ripples (150-200Hz). Mixed models were computed separately for REM and NREM in dark and light period, with age as group factor and electrode and frequency as repeated factors. Results Two-way interactions were found between age and frequency and between electrode and frequency, for NREM and REM in dark and light periods. Each frequency band, except ripples, showed a topographical signature in NREM and REM (e.g. higher power in anterior compared to posterior areas for delta band in NREM sleep). These relative patterns did not change in older mice, but global changes occurred on all electrodes: in older mice, delta power was globally higher in NREM and REM sleep whereas sigma power was lower in REM sleep. Conclusion Age-related changes in spectral power of sleeping mice do not vary according to brain topography as in humans. Sleep deprivation studies are needed to investigate whether age is associated with global changes in sleep homeostasis in mice. Support This work has been supported by the Quebec Fonds de Recherche Nature et Technologies (FQRNT).

Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.

Orexin receptor antagonists are clinically useful for treating insomnia, but thorough blockade of orexin signaling could cause narcolepsy-like symptoms. Specifically, while sleepiness is a desirable effect, an orexin antagonist could also produce cataplexy, sudden episodes of muscle weakness often triggered by strong, positive emotions. In this study, we examined the effects of dual orexin receptor antagonists (DORAs), lemborexant (E2006) and almorexant, on sleep-wake behavior and cataplexy during the dark period in wild-type (WT) mice and prepro-orexin knockout (OXKO) mice. In WT mice, lemborexant at 10 and 30 mg/kg quickly induced NREM sleep in a dose-dependent fashion. In contrast, lemborexant did not alter sleep-wake behavior in OXKO mice. Under the baseline condition, cataplexy was rare in lemborexant-treated WT mice, but when mice were given chocolate as a rewarding stimulus, lemborexant dose-dependently increased cataplexy. Almorexant produced similar results. Collectively, these results demonstrate that DORAs potently increase NREM and REM sleep in mice via blockade of orexin signaling, and higher doses can cause cataplexy when co-administered with a likely rewarding stimulus.

Life Without Dreams: Muscarinic Receptors Are Required to Regulate REM Sleep in Mice

Mammalian sleep comprises REM and NREM stages, but the regulation mechanisms are unclear. In this issue of Cell Reports, Niwa etal. (2018) comprehensively knocked out cholinergic receptors in mice and found that muscarinic signaling is crucial for REM sleep and possibly important for NREM sleep.

0200 DIRECT ACTIVATION OF G-PROTEIN-COUPLED INWARD RECTIFYING K+ CHANNELS PROMOTE SLEEP IN RODENTS

The most common type of sleep disorder is insomnia which is characterized by difficulty falling asleep and/or maintaining sleep. Chronic insomniacs respond poorly to current treatments including benzodiazepines and non-benzodiazepines. Activation of G-protein-gated inward rectifying K channels (GIRKs) by GABAB agonists baclofen or γ-hydroxybutyric acid (GHB) predominantly promote non-rapid eye movement (NREM) sleep in rodents and humans. GHB especially reduces sleep fragmentation in narcoleptic patients. The present study explored the link between direct GIRK activation and sleep regulation in rodents using our potent and selective GIRK channel activator ML297. Whole-cell patch clamp recordings from hypocretin/orexin-EGFP neurons and extracellular recordings of mouse hippocampal CA1 area in mouse brain slices were made to study cellular and synaptic actions of ML297. Wake activity and locomotion were measured using the noninvasive behavior monitoring system SmartCageTM. Furthermore, wakefulness, REM and NREM sleep were determined using the electroencephalogram/electromyogram (EEG/EMG) in wild type mice (C57BL/C) implanted with electrodes. Bath-application of ML297 (5µM) hyperpolarized resting potential, decreased membrane input resistance and blocked spontaneous firing of action potentials in hypocretin/orexin neurons. These actions were reversed after prolonged washout. ML297 (5–50µM) produced no significant effects on normal synaptic activity measured by input-output of field postsynaptic excitatory potentials and an evoked single population of spikes in the hippocampal CA1 area, suggesting ML297 principally causes long-lasting postsynaptic inhibition. Using our noninvasive SmartCageTM system we observed that ML297 (30mg/kg, i.p.) caused a prolonged inhibition of wake activity and locomotion in mice. The EEG/EMG recordings confirmed that ML297 (30mg/kg, i.p.) significantly decreased wakefulness and revealed an increase in NREM sleep without affecting REM sleep in mice. The present study for the first time has demonstrated that direct action of GIRK produces similar sleep regulation to GABAB receptor-mediated modulation. Since GIRKs channels are predominantly expressed in principal excitatory neurons, inhibition of neuronal excitability and depression of the arousal system may powerfully modulate sleep. Direct GIRK activators may present an innovative approach for treatment of chronic insomnia as well as other sleep disorders. This work was supported by NIH grants: R42 HL084990, R44 AG043203, and R44 NS086343.

Chronic sleep deprivation alters theta and gamma powers during REM sleep in mice

Chronic sleep deprivation alters theta and gamma powers during REM sleep in mice

Selective coupling between theta phase and neocortical fast gamma oscillations during REM-sleep in mice.

BackgroundThe mammalian brain expresses a wide range of state-dependent network oscillations which vary in frequency and spatial extension. Such rhythms can entrain multiple neurons into coherent patterns of activity, consistent with a role in behaviour, cognition and memory formation. Recent evidence suggests that locally generated fast network oscillations can be systematically aligned to long-range slow oscillations. It is likely that such cross-frequency coupling supports specific tasks including behavioural choice and working memory.Principal FindingsWe analyzed temporal coupling between high-frequency oscillations and EEG theta activity (4–12 Hz) in recordings from mouse parietal neocortex. Theta was exclusively present during active wakefulness and REM-sleep. Fast oscillations occurred in two separate frequency bands: gamma (40–100 Hz) and fast gamma (120–160 Hz). Theta, gamma and fast gamma were more prominent during active wakefulness as compared to REM-sleep. Coupling between theta and the two types of fast oscillations, however, was more pronounced during REM-sleep. This state-dependent cross-frequency coupling was particularly strong for theta-fast gamma interaction which increased 9-fold during REM as compared to active wakefulness. Theta-gamma coupling increased only by 1.5-fold.SignificanceState-dependent cross-frequency-coupling provides a new functional characteristic of REM-sleep and establishes a unique property of neocortical fast gamma oscillations. Interactions between defined patterns of slow and fast network oscillations may serve selective functions in sleep-dependent information processing.

Characterization of the bout durations of sleep and wakefulness

Study objectives(a) Develop a new statistical approach to describe the microarchitecture of wakefulness and sleep in mice; (b) evaluate differences among inbred strains in this microarchitecture; (c) compare results when data are scored in 4-s versus 10-s epochs. DesignStudies in male mice of four inbred strains: AJ, C57BL/6, DBA and PWD. EEG/EMG were recorded for 24h and scored independently in 4-s and 10-s epochs. Measurements and resultsDistribution of bout durations of wakefulness, NREM and REM sleep in mice has two distinct components, i.e., short and longer bouts. This is described as a spike (short bouts) and slab (longer bouts) distribution, a particular type of mixture model. The distribution in any state depends on the state the mouse is transitioning from and can be characterized by three parameters: the number of such bouts conditional on the previous state, the size of the spike, and the average length of the slab. While conventional statistics such as time spent in state, average bout duration, and number of bouts show some differences between inbred strains, this new statistical approach reveals more major differences. The major difference between strains is their ability to sustain long bouts of NREM sleep or wakefulness. Scoring mouse sleep/wake in 4-s epochs offered little new information when using conventional metrics but did when evaluating the microarchitecture based on this new approach. ConclusionsStandard statistical approaches do not adequately characterize the microarchitecture of mouse behavioral state. Approaches based on a spike-and-slab provide a quantitative description.

Ectopic Overexpression of Orexin Alters Sleep/Wakefulness States and Muscle Tone Regulation during REM Sleep in Mice

Orexins (also called hypocretins), which are neuropeptides exclusively expressed by a population of neurons specifically localized in the lateral hypothalamic area, are critically implicated in the regulation of sleep/wake states. Orexin deficiency results in narcoleptic phenotype in rodents, dogs, and humans, suggesting that orexins are important for maintaining consolidated wakefulness states. However, the physiological effect of constitutive increased orexinergic transmission tone, which might be important for understanding the effects of orexin agonists that are promising candidates for therapeutic agents of narcolepsy, has not been fully characterized. We report here the sleep/wakefulness abnormalities in transgenic mice that exhibit widespread overexpression of a rat prepro-orexin transgene driven by a β-actin/cytomegalovirus hybrid promoter (CAG/orexin transgenic mice). CAG/orexin mice exhibit sleep abnormalities with fragmentation of non-rapid eye movement (REM) sleep episode and a reduction in REM sleep. Non-REM sleep was frequently disturbed by short episodes of wakefulness. EEG/EMG studies also reveal incomplete REM sleep atonia with abnormal myoclonic activity during this sleep stage. These results suggest that endogenous orexinergic activity should be appropriately regulated for normal maintenance of sleep states. Orexinergic transmission should be activated during wakefulness, while it should be inactivated or decreased during sleep state to maintain appropriate vigilance states.

Central Deficiency of Corticotropin-Releasing Hormone Receptor Type 1 (CRH-R1) Abolishes Effects of CRH on NREM But Not on REM Sleep in Mice

Corticotropin-releasing hormone (CRH) is the major activator of the hypothalamic-pituitary-adrenocortical (HPA) system and orchestrates the neuroendocrine, autonomous as well as behavioral responses to stress. Many studies suggest an influence of CRH on sleep-wake regulation even in the absence of stressors. However, none of these studies yet clearly distinguished between central and peripheral effects of CRH. Therefore, we investigated in CNS-specific CRH receptor type 1 deficient mice whether centrally administered CRH could induce its sleep-wake modulatory effects without peripheral induction of HPA activity. Male mice (C57BL/6J, CNS-specific CRH-R1 knockout [CKO] mice and their control littermates [CL]) were intracerebroventricularily (i.c.v.) injected with vehicle or 3 different doses of CRH shortly before the beginning of the light period. Electroencephalogram (EEG) and electromyogram (EMG) were monitored to compare the effects of CRH on vigilance states with or without presence of central CRH-R1. To quantify HPA-axis reactivity to CRH injections in CKO and CL animals, blood samples were analyzed to determine plasma corticosterone concentrations. I.c.v. injections of CRH promoted wakefulness while decreasing NREMS in C57BL/6J and CRH-R1 CL animals, whereas such changes were not exerted in CKO mice. However, REMS suppression after CRH application persisted in all animals. I.c.v. injected CRH increased plasma corticosterone levels in both CL and CKO mice. The results demonstrated that CRH has a major impact on wake and NREMS regulation which is predominantly mediated through central CRH-R1. Peripheral actions of CRH, i.e., elevated HPA activity, may interfere with its central effects on REMS but not on NREMS suppression.